J&J Reports Low Rates Of Treatment-Related Events For Rybrevant Faspro Plus Lazcluze At Wclc 2026
JNJ•J&J reports low rates of treatment-related events
- J&J reports low rates of treatment-related events for Rybrevant Faspro plus Lazcluze at WCLC 2026.
- Fewer than 1% discontinue Rybrevant Faspro plus Lazcluze due to treatment-related events at one year.
